GLB1 and Alzheimer disease: Due to changes in the number of neuroglia markers in comparison to the baseline in the normal participants, the mechanism of the novel drugs in influencing AD is suggested to be evaluated through Galectin-3 (Gal-3), which is a beta-galactosidase binding protein used as a biomarker of microglial function (Boza-Serrano et al., 2022).